[1] |
李锁, 冯素英. BP180相关自身免疫性水疱病的研究进展[J]. 中华皮肤科杂志, 2019,52(1):50⁃52. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.017.
|
[2] |
Drucker DJ, Nauck MA. The incretin system: glucagon⁃like peptide⁃1 receptor agonists and dipeptidyl peptidase⁃4 inhibitors in type 2 diabetes[J]. Lancet, 2006,368(9548):1696⁃1705. doi: 10.1016/S0140⁃6736(06)69705⁃5.
|
[3] |
Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case⁃control study from France and Switzerland[J]. J Am Acad Dermatol, 2018,78(6):1090⁃1096. doi: 10.1016/j.jaad.2017.12.038.
|
[4] |
Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid[J]. J Invest Dermatol, 2016,136(11):2201⁃2210. doi: 10.1016/j.jid.2016.06.622.
|
[5] |
Nishie W. Dipeptidyl peptidase IV inhibitor⁃associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics[J]. Immunol Med, 2019,42(1):22⁃28. doi: 10. 1080/25785826.2019.1619233.
|
[6] |
Mai Y, Nishie W, Izumi K, et al. Preferential reactivity of dipeptidyl peptidase⁃IV inhibitor⁃associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180[J]. Front Immunol, 2019,10:1224. doi: 10.3389/fimmu.2019. 01224.
|
[7] |
陈金波, 崔天盆, 陈柳青, 等. 自身免疫性大疱性皮肤病的实验诊断[J]. 中华检验医学杂志, 2015,38(12):797⁃800. doi: 10.3760/cma.j.issn.1009⁃9158.2015.12.002.
|
[8] |
Hayakawa T, Teye K, Hachiya T, et al. Clinical and immunological profiles of anti⁃BP230⁃type bullous pemphigoid: restriction of epitopes to the C⁃terminal domain of BP230, shown by novel ELISAs of BP230⁃domain specific recombinant proteins[J]. Eur J Dermatol, 2016,26(2):155⁃163. doi: 10.1684/ejd.2015.2719.
|
[9] |
Shih YC, Wang B, Yuan H, et al. Role of BP230 autoantibodies in bullous pemphigoid[J]. J Dermatol, 2020,47(4):317⁃326. doi: 10.1111/1346⁃8138.15251.
|
[10] |
Sawada K, Sawada T, Kobayashi T, et al. A case of anti⁃BP230 antibody⁃positive bullous pemphigoid receiving DPP⁃4 inhibitor[J/OL]. Immunol Med, 2020:1⁃3[2020⁃07⁃07]. doi: 10.1080/25785826.2020.1787584. https://www.tandfonline.com/doi/full/10.1080/25785826.2020.1787584.
|
[11] |
Zheng M, Ujiie H, Iwata H, et al. Characteristics of IgG subclasses and complement deposition in BP230⁃type bullous pemphigoid[J]. J Eur Acad Dermatol Venereol, 2019,33(3):595⁃600. doi: 10.1111/jdv.15325.
|
[12] |
Kawaguchi Y, Shimauchi R, Nishibori N, et al. Dipeptidyl peptidase⁃4 inhibitors⁃associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients[J]. J Diabetes Investig, 2019,10(2):392⁃398. doi: 10.1111/jdi.12877.
|